Want to see BLCO full AI Analyst Report?
Revenue by Segment
Shows how much revenue each business segment generates, highlighting core strengths and areas of growth or decline within the company’s operations.
Since Q4 2023 Bausch + Lomb’s revenue mix materially shifted: Pharmaceuticals moved from a secondary role to a sustained growth driver, while Surgical shows steady, incremental upside and stronger Q4s. Vision Care remains largest but its growth is steadier, making the business less dependent on one cyclical segment. That diversification reduces top-line concentration risk and signals that recent product/market momentum in pharma and surgical could underpin more durable revenue growth going forward.
BLCO Revenue by Segment
| Date | Vision Care | Surgical | Pharmaceuticals |
|---|---|---|---|
| Sep 30, 2026 | $774.00M | $234.00M | $367.00M |
| Jun 30, 2026 | $784.00M | $256.00M | $354.00M |
| Mar 31, 2026 | $711.00M | $228.00M | $305.00M |
| Dec 31, 2025 | $778.00M | $249.00M | $378.00M |
| Sep 30, 2025 | $736.00M | $215.00M | $330.00M |
| Jun 30, 2025 | $753.00M | $216.00M | $309.00M |
| Mar 31, 2025 | $656.00M | $214.00M | $267.00M |
| Dec 31, 2024 | $723.00M | $231.00M | $326.00M |
| Sep 30, 2024 | $684.00M | $206.00M | $306.00M |
| Jun 30, 2024 | $697.00M | $209.00M | $310.00M |
| Mar 31, 2024 | $635.00M | $197.00M | $267.00M |
| Dec 31, 2023 | $662.00M | $204.00M | $307.00M |
| Sep 30, 2023 | $648.00M | $185.00M | $174.00M |
| Jun 30, 2023 | $646.00M | $195.00M | $194.00M |
| Mar 31, 2023 | $587.00M | $183.00M | $161.00M |
| Dec 31, 2022 | $626.00M | $188.00M | $182.00M |
| Sep 30, 2022 | $598.00M | $172.00M | $172.00M |
| Jun 30, 2022 | $589.00M | $184.00M | $168.00M |
| Mar 31, 2022 | $560.00M | $174.00M | $155.00M |
| Dec 31, 2021 | $626.00M | $198.00M | $177.00M |
| Sep 30, 2021 | $605.00M | $173.00M | $171.00M |
| Jun 30, 2021 | $556.00M | $185.00M | $193.00M |
| Mar 31, 2021 | $556.00M | $162.00M | $163.00M |